GCANRx

GCANRx is a clinical stage biopharmaceutical company focused on the development and commercialization of an innovative pharma-grade therapeutic that reduces disruptive symptoms in patients suffering from neuropsychiatric disorders without the side effects of existing medications. GCANRx has teamed up with a world renowned research center to treat 100 children diagnosed with ASD and related behavioral problems, with a combination of CBD, and additional proprietary compounds for up to 24 weeks. The purpose of the double-blind, placebo controlled study is to prove the efficacy of a new therapeutic in treating the core symptoms of Autism (ASD).